<?xml version="1.0" encoding="UTF-8"?>
<p>Lipid metabolism disorders are commonly found in people who are obese. The prevalence of obesity and overweight has dramatically increased in developed and developing countries due to the increased consumption of high-fat diets and the daily intake of alcohol [
 <xref rid="B1" ref-type="bibr">1</xref>]. Obesity and overweight are associated with hyperglycemia and dyslipidemia in children and adolescents [
 <xref rid="B2" ref-type="bibr">2</xref>]. Dyslipidemia is a group of metabolic disorders and a noncommunicable disease manifested by elevation of serum cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations and a decrease in high-density lipoprotein (HDL) cholesterol concentration. It is one of the major risk factors associated with atherosclerosis which leads to the development of cardiovascular diseases and increased mortality [
 <xref rid="B3" ref-type="bibr">3</xref>]. Orlistat is a weight loss agent which inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract delaying absorption of dietary fat that is approved by the Food and Drug Administration for the treatment of obesity. It also improves total cholesterol and low-density lipoprotein for the treatment of dyslipidemia. The major side effects, which occur at an early stage of treatment with orlistat, are mainly gastrointestinal [
 <xref rid="B4" ref-type="bibr">4</xref>]. Simvastatin is a HMG-CoA reductase inhibitor which is commonly used to decrease blood cholesterol and triglyceride levels. The major adverse effects of statins are myositis, myalgia [
 <xref rid="B5" ref-type="bibr">5</xref>], rhabdomyolysis [
 <xref rid="B6" ref-type="bibr">6</xref>], and hepatic disorders [
 <xref rid="B7" ref-type="bibr">7</xref>].
</p>
